These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31094589)

  • 1. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.
    Restelli U; Saibene G; Nardulli P; Di Turi R; Bonizzoni E; Scolari F; Perrone T; Croce D; Celio L
    BMJ Open; 2017 Aug; 7(7):e015645. PubMed ID: 28765126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
    Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
    Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
    Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
    Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
    Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
    Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment.
    Giuliani J; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):505-508. PubMed ID: 31379219
    [No Abstract]   [Full Text] [Related]  

  • 9. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data.
    Giuliani J; Bonetti A
    Curr Opin Oncol; 2020 Jul; 32(4):269-273. PubMed ID: 32541312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
    Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
    Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
    Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
    J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
    Navari RM
    Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
    Keating GM
    Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
    Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
    Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.